Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bel-sar · 1 trial · 4 indications
Tumor Progression
| Arm | Type | Description |
|---|---|---|
| High dose bel-sar treatment arm & laser application | EXPERIMENTAL | High dose of bel-sar + laser application |
| Low dose bel-sar treatment arm & laser application | EXPERIMENTAL | Low dose of bel-sar + laser application |
| Sham control arm & sham laser | SHAM_COMPARATOR | Sham injection + sham laser |
| Name | Type | Description |
|---|---|---|
| Bel-sar | DRUG | Bel-sar via suprachoroidal administration followed by laser application. |
| Suprachoroidal Microinjector | DEVICE | Suprachoroidal injection device |
| Infrared Laser | DEVICE | Laser application |
| Sham Infrared Laser | DEVICE | Sham laser application |
| Sham Microinjector | DEVICE | Sham injection device |
Inclusion Criteria: * Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL/CM) * Have no evidence of metastatic disease confirmed by imaging * Be treatment naive for IL/CM (subjects who received PDT may be eligible) Exclusion Criteria: * Have known contraindications ...
Bel-sar, also known as belzupacap sarotalocan or AU-011, is an investigational small molecule being developed for the treatment of choroidal melanoma, including primary indeterminate lesions and small choroidal melanoma. It is also being studied for related conditions such as uveal melanoma and ocular melanoma.
Bel-sar is a small molecule, but its specific molecular target has not been disclosed. The drug is being studied for its efficacy and safety in treating choroidal melanoma, a type of eye cancer, though the exact mechanism of action is not publicly detailed.
Bel-sar is being developed by Aura Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AURA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with choroidal melanoma.
Bel-sar is currently in Phase 3 clinical development. It is being evaluated in a randomized, double-blind, sham-controlled trial for the treatment of primary indeterminate lesions or small choroidal melanoma. The drug is investigational and has not yet been approved by regulatory authorities.
Bel-sar is being studied in a Phase 3 clinical trial with the identifier NCT06007690. This trial is a randomized, masked, controlled study comparing Bel-sar treatment to sham control in subjects with primary indeterminate lesions or small choroidal melanoma. The trial is active but not recruiting, with an enrollment of 108 participants.
Yes, Bel-sar is also known as belzupacap sarotalocan and AU-011. These names refer to the same investigational drug being developed by Aura Biosciences for the treatment of choroidal melanoma. The drug is currently in Phase 3 clinical trials.